Alcyone Lifesciences
Pioneers next-generation intra-CSF CNS precision gene-based therapeutics for complex neurological conditions.
Launch date
Employees
Market cap
-
Enterprise valuation
€84—125m (Dealroom.co estimates Jun 2021.)
Ayer Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $1.8m | Series A | |
| N/A | $1.0m | Seed | |
$4.0m | Series B | ||
| N/A | $3.6m | Early VC | |
| N/A | $5.1m | Early VC | |
$23.0m | Late VC | ||
| Total Funding | €35.0m | ||
Recent News about Alcyone Lifesciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.